Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Mallinckrodt
UBS
US Army
Covington
Queensland Health
Chubb
Cantor Fitzgerald
McKesson

Generated: September 23, 2018

DrugPatentWatch Database Preview

Sanofi Us Company Profile

« Back to Dashboard

What is the competitive landscape for SANOFI US, and what generic alternatives to SANOFI US drugs are available?

SANOFI US has four approved drugs.

There are twenty US patents protecting SANOFI US drugs.

Summary for Sanofi Us
US Patents:20
Tradenames:4
Ingredients:2
NDAs:4

Drugs and US Patents for Sanofi Us

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Us Services TOUJEO MAX SOLOSTAR insulin glargine recombinant SOLUTION;SUBCUTANEOUS 206538-002 Mar 26, 2018 RX Yes Yes 9,775,954 ➤ Sign Up Y ➤ Sign Up
Sanofi Us Services TOUJEO MAX SOLOSTAR insulin glargine recombinant SOLUTION;SUBCUTANEOUS 206538-002 Mar 26, 2018 RX Yes Yes 9,604,009 ➤ Sign Up Y ➤ Sign Up
Sanofi Us ZANTAC 150 ranitidine hydrochloride TABLET;ORAL 021698-001 Aug 31, 2004 OTC Yes Yes ➤ Sign Up ➤ Sign Up
Sanofi Us Services TOUJEO SOLOSTAR insulin glargine recombinant SOLUTION;SUBCUTANEOUS 206538-001 Feb 25, 2015 RX Yes Yes 9,233,211 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Sanofi Us

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Us ZANTAC 150 ranitidine hydrochloride TABLET;ORAL 021698-002 Mar 13, 2007 5,098,715 ➤ Sign Up
Sanofi Us ZANTAC 75 ranitidine hydrochloride TABLET;ORAL 020520-001 Dec 19, 1995 4,880,636*PED ➤ Sign Up
Sanofi Us ZANTAC 75 ranitidine hydrochloride TABLET;ORAL 020520-001 Dec 19, 1995 4,521,431*PED ➤ Sign Up
Sanofi Us ZANTAC 75 ranitidine hydrochloride TABLET;ORAL 020520-001 Dec 19, 1995 4,128,658 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SANOFI US drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 150 mg ➤ Subscribe 2007-10-30

Supplementary Protection Certificates for Sanofi Us Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
226 Luxembourg ➤ Sign Up PRODUCT NAME: COMBINATION D'INSULINE DEGLUDEC ET INSULINE ASPARTE SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; FIRST REGISTRATION DATE: 20130121
00597 Netherlands ➤ Sign Up PRODUCT NAME: INSULINE DEGLUDEC EN INSULINE ASPART; REGISTRATION NO/DATE: EU/1/12/806/001EU/1/12/806/004EU/1/12/806/005EU/1/12/806/007EU/1/12/806/008 2013210121
60026 Netherlands ➤ Sign Up PRODUCT NAME: INSULINUM LISPRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/96/007/001 - EU/1/96/007/003 19960430
C0020 France ➤ Sign Up PRODUCT NAME: INSULIN DETEMIR; NAT. REGISTRATION NO/DATE: EU/1/04/278/001 20040601; FIRST REGISTRATION: LI - 56370 20031110
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Chinese Patent Office
Accenture
Chubb
Julphar
QuintilesIMS
Merck
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.